About Us
Tres Alchemix is an AI-native biotechnology company developing a predictive drug-design platform to create next-generation small-molecule therapies. By integrating multi-omic and multimodal datasets with proprietary quantum-chemical calculation methods, the company is building a human in silico model capable of forecasting the efficacy and safety of novel compounds. Founded in 2023 in Fukuoka, Japan, Tres Alchemix is expanding its operations in the United Kingdom with a new laboratory at The Oxford Science Park.
Press releases
Tres Alchemix Closes $4.4 Million Series A To Advance AI Drug-Design...
Funds will support R&D expansion in Oxford, UK, and the design of novel drugs through direct prediction of therapeutic and potential adverse... read more
26.09.2025 • By Tres Alchemix Co. Ltd.
